Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01578928
Other study ID # CSOM230B2126
Secondary ID 2011-005922-23
Status Completed
Phase Phase 1
First received
Last updated
Start date May 2012
Est. completion date May 2014

Study information

Verified date September 2020
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of pasireotide,the PK of pasireotide in subjects with different degrees of renal impairment.


Description:

This is a phase I, open-label, multicenter, single dose study to evaluate the PK and safety of pasireotide s.c. injection in subjects with varying degrees of renal impairment compared to healthy subjects with normal renal function. Subjects will be classified by their respective degree of renal functions (normal, mild, moderate, severe, and ESRD (End Stage Renal Disease) according to eGFR as determined at the screening visit.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date May 2014
Est. primary completion date May 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion criteria: Subjects eligible for inclusion in this study have to meet all of the following criteria: 1. Written informed consent obtained prior to any screening procedures. 2. Subjects must be able to communicate well with the investigator and comply with the requirements of the study procedures 3. Male or female subjects between 18 and 75 years of age, inclusive. 4. Vital Signs at screening and baseline which are within the following ranges: - Oral body temperature: = 35.0 and = 37.5 °C - Pulse rate: 40-90 bpm 5. Subjects must have a BMI between 20 kg/m2 and 30 kg/m2 and weigh at least 50 kg and no more than 120 kg. 6. Subjects must be willing to comply with dietary, fluid, and lifestyle restrictions (from day-1 to study completion). 7. Other than renal impairment, subjects must be stable and appropriately managed relative to chronic diseases (such as diabetes and hypertension) as determined by past medical history, physical examination, electrocardiogram, and laboratory tests for chemistry and hematology. For renal impairment subjects only 8. Subjects must have stable renal disease without evidence of renal progressive disease (stable renal disease is defined as no significant change, such as, stable eGFR, for 12 weeks prior to study entry). 9. Blood pressure (3 minutes resting before measurement) in the supine position: - Systolic: 90-165 mmHg - Diastolic: 60-110 mmHg For control subjects only 10. Subjects must be matched to at least one renal impaired subject by gender, age (±10 years), body weight (±20%), BMI (±5%) and race. 11. Blood pressure (3 minutes resting before measurement) in the supine position: - Systolic: 90-140 mmHg - Diastolic: 50-90 mmHg Exclusion criteria: Subjects eligible for this study must not meet any of the following criteria: 1. Clinically significant abnormal laboratory values at the screening evaluation or at the baseline re-evaluation, excluding those normally associated with mild to severe degree of renal impairment or the primary cause of renal insufficiency 2. Use of any over-the-counter medications or vitamins or herbal/natural supplements during 2 weeks prior to dosing (acetaminophen is acceptable, and must be documented in the Concomitant Medications/Non-Drug Therapies page of the CRF) 3. Current medical history of the following: - Sustained or clinically significant cardiac arrhythmias - History of syncope or family history of idiopathic sudden death - Risk factors for torsades de pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high grade AV block - Screening QTcF > 450ms - Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure - Concomitant medications known to increase the QT interval 4. Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation 5. Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing or other amount considered to compromise the health of the subject if previous history of anemia exists 6. Significant acute illness within the two weeks prior to dosing 7. History of immunocompromise, including a positive HIV (ELISA and Western blot) test result 8. History of allergies to the investigational compound/compound class being used in the study 9. A positive Hepatitis B surface antigen (HBsAg) or positive HCV antibody 10. History of drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations 11. History of liver disease, such as cirrhosis or chronic active hepatitis B and C. 12. Known gallbladder or bile duct disease, acute or chronic pancreatitis 13. Baseline ALT or AST > ULN 14. Baseline total bilirubin > 1.5x ULN 15. Subjects on dialysis 16. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 5 times the terminal half-life of study treatment (6 days). Highly effective contraception methods include: - Total abstinence or - Male or female sterilization or - Combination of any two of the following (a+b or a+c, or b+c): - Use of oral, injected or implanted hormonal methods of contraception - Placement of an intrauterine device (IUD) or intrauterine system (IUS) - Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository 17. Sexually active males unless they use a condom during intercourse while taking drug and for 5 half-lives (6 days) after stopping SOM230 medication and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid. 18. Potentially unreliable or vulnerable subjects (e.g. person kept in detention) and those judged by the investigator to be unsuitable for the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SOM230


Locations

Country Name City State
Germany Novartis Investigative Site Berlin
South Africa Novartis Investigative Site Bloemfontein Free State

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Germany,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma and Urine PK parameters Description: Cmax, AUCinf, AUClast, CL/F, CLR, glucose, insulin, glucagon pre-dose (-1 min) and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12, 24, 36, 48, 72, 96, 120 and 122 hours post-dose
Secondary Additional PK parameters Description: Vz/F, T1/2, Fu, Cmax,u, AUCinf,u, AUClast,u, CLu/F and Vu/F pre-dose (-1 min) and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 24, 36, 48, 72, 96, 120 and 122 hours post-dose
See also
  Status Clinical Trial Phase
Completed NCT01937975 - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) Phase 1
Completed NCT03284164 - Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex Phase 1
Completed NCT05992155 - A Study of TAK-279 in Adults With or Without Kidney Problems Phase 1
Completed NCT05004311 - The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics Phase 1
Completed NCT04963738 - A Study of JNJ-73763989 in Adult Participants With Renal Impairment Phase 1
Terminated NCT02508740 - Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Phase 1
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Terminated NCT00984113 - Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00750620 - A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00842868 - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases N/A
Completed NCT00499187 - Fanconi Syndrome Due to ARVs in HIV-Infected Persons Phase 4
Completed NCT01331941 - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function Phase 1
Completed NCT05489614 - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment Phase 1
Completed NCT03259087 - Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005) Phase 1
Completed NCT05086107 - Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment Phase 1
Recruiting NCT05349851 - Bowel Cleansing With Renal Impairment
Completed NCT03660241 - A Renal Impairment Study for PF-04965842 Phase 1
Recruiting NCT06037031 - A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function Phase 1
Completed NCT03289208 - Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment Phase 1
Completed NCT02942810 - To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment Phase 1